Dong-A ST launches Xcopri in South Korea seven years after U.S. approval
AI Summary- Dong-A ST launched Xcopri tablets in South Korea for adult partial-onset seizure patients.
- About 360,000 South Korean patients receive epilepsy treatment, with 30% estimated drug-resistant.
- SK Biopharmaceuticals developed Xcopri, which won U.S. FDA approval in 2019.